Plenty of big pharma companies are betting on weight-loss drugs, including Pfizer (PFE), Novo Nordisk (NVO), and Eli Lilly (LLY). But there are plenty of other companies, including startups, that are trying to get a piece of the weight-loss market.

Portal Innovations Co-Founder and CEO John Flavin is investing in some of those endeavors. "We're seeing a pipeline of about 240 companies that are either developing or are moving toward the market with obesity or cardiometabolic drugs," he says. Flavin cites a company he is investing in that targets a different "pathway" than GLP-1s to fight obesity.

Flavin thinks that though a lot of money is being invested into the weight-loss market, plenty of cash will continue to flow to other areas in the biotech space. The big reason? Both venture capitalists and big pharmaceutical companies have money to invest.

Watch the video above to hear where else Flavin says money is being invested in the biotech space.

For more expert insight and the latest market action, click here to watch this full episode of Asking for a Trend.

This post was written by Stephanie Mikulich.